Christoph Varenhorst has been appointed new Medical Director at Pfizer Sweden.
Varenhorst is a cardiologist and has long experience from both clinical work and research from Uppsala University Hospital and Uppsala Clinical Research Center. His most recent position has been Chief Physician and Researcher at Uppsala University Hospital and Uppsala Clinical Research Center. He has an extensive, both locally and internationally, network as member of boards and commissioner in several scientific societies, including the European Society of Cardiology. He started his new position at Pfizer on January 1st 2018.
The patient perspective has always been important to me
“It is really exciting and stimulating to be able to gather my experiences from clinical work and academic research and now take on a position within a research based pharmaceutical company like Pfizer. I look forward to be a part of, develop and contribute in giving our patients access to more effective treatments. The patient perspective has always been important to me so it feels very good that that is a fundamental keyword in Pfizer’s work. In order to reach that goal we must work effectively together: pharma companies, the healthcare sector, patient representatives and academic researchers,” says Varenhorst.
John Brun, previously Medical Director, will continue working part time at Pfizer as Life Science Director. He will also work part time with strategic questions within LIF, the Research based Pharmaceutical Industry in Sweden.
Photo of Christoph Varenhorst: Brigitte Grenfeldt
